The case
A 67-y-old man had been undergoing prostate-specific antigen (PSA) testing as part of his routine private medical screening. He had a raised PSA level (5.1 ng/ml) in July 2002; however, he was told he was unlikely to have cancer and no further investigations were performed. Over a 16-month period, his PSA level increased to 7.3 ng/ml. He underwent prostatic biopsy (10 biopsies from eight sites) in February 2004, which revealed Gleason score 6 (3 þ 3) prostate cancer at four of the eight sites sampled. He saw a second specialist and had magnetic resonance imaging and bone scans, which were both negative. In discussions concerning treatment options (external-beam radiotherapy, radical prostatectomy, brachytherapy), his chief concern was that a cure could be achieved and confirmed. He elected to undergo radical prostatectomy and, despite being told that he had about a 50% chance of having organ-confined disease based on the Partin tables, believed he would be cured. The patient was fully potent prior to surgery. He underwent an open retropubic radical prostatectomy, via a transverse lower abdominal incision, with bilateral nerve sparing using the anatomical technique described by Walsh, and lymph node sampling from the obturator fossa (four nodes on the left, five on the right). Both neurovascular bundles appeared intact after surgery. Blood loss was modest, postoperative recovery uneventful, and he was fully continent on removal of the catheter on postoperative day 14. The postprostatectomy pathology report revealed extensive intraprostatic disease with an estimated tumor volume of 5.6 cm 3 , a positive surgical margin posterolaterally, and one positive lymph node ( Figure 1) (pT3, N1) . His postprostatectomy PSA level was 0.25 ng/ml. After discussion of his treatment options (radiotherapy, hormonal therapy, chemotherapy), he initially considered hormonal therapy. However, after investigating complementary therapies, he began taking apricot kernels (a source of vitamin B17) and is convinced of their benefits. If his PSA rises, he has decided to take nonsteroidal antiandrogen (bicalutamide ('Casodex') 150 mg) monotherapy rather than castrationbased therapy as he is keen to preserve his libido. In March 2005, his PSA level was 0.07 ng/ml. At approximately 1-y postprostatectomy, he is able to achieve erections sufficient for intercourse, but the rigidity of these is reduced; orgasms are normal.
Discussion
Serum PSA screening can detect prostate cancer in asymptomatic men with early localized and, therefore, potentially curable disease. A PSA level 44 ng/ml is considered abnormal for men of any age. However, while at least 25% of men with a PSA level in the 4-10 ng/ml range have prostate cancer, 1 the remaining 75% have benign disease. The decision to pursue a biopsy will take into account not only the PSA level, but the patient's age, family history of cancer, and personal circumstances. In this case, prostate biopsy was not undertaken after the first PSA test yielded a result 44 ng/ml (5.1 ng/ml) but delayed until the PSA level was 47 ng/ml. The subsequent diagnostic work-up indicated cT2b prostate cancer (Gleason score 6 (3 þ 3)).
Choice and outcome of primary therapy
Pretreatment nomograms, such as the Partin tables, 2 are an invaluable aid when counseling patients faced with initial treatment decisions for clinically localized prostate cancer. According to the Partin tables, 2 this patient, with cT2b disease, a PSA level of 7.3 ng/ml, and a Gleason score of 6, had a 49% chance (95% confidence intervals (CI) 43%, 54%) of having organ-confined disease and a very low risk of lymph node-positive disease (2%, 95% CI 1%, 3%).
In selecting primary therapy, the patient's main concern was not only for cure but that this cure could be verified. Given that following surgery, the complete removal of detectable tumor can potentially be demonstrated, he decided to undergo radical prostatectomy, and despite the Partin table predictions, believed he would be cured. Fully potent prior to his diagnosis, the patient was eager to keep his sexual function. A bilateral nerve-sparing procedure was therefore planned. The patient was informed that anatomical findings during surgery could preclude complete nerve sparing and that even if bilateral nerve sparing was possible, the probability of potency 1-y postprostatectomy was only 50-60%. Both neurovascular bundles appeared to have been preserved at surgery and the patient has satisfactory erectile function 1-y postprostatectomy. However, the positive posterolateral surgical margin indicates incomplete tumor excision. Furthermore, one of the nine lymph nodes removed during surgery was positive for metastases (Figure 1 ). This unfavorable lymph node pathology was unexpected given the Partin table predictions. 2 
Accuracy of pretreatment nomograms
The Partin tables were developed based on data from a large series of men treated at a single US center. 2 These tables correctly predict pathologic stage in approximately 75% of similar patients and there is currently no better tool to aid preoperative decision-making. 2, 3 Nomograms that predict postoperative PSA failure rates from pretreatment characteristics can be used as an alternative or complementary tool to the Partin tables.
Postoperative restaging allows re-evaluation of a patient's prognosis and assessment of the need for additional treatments. Nomograms that combine both clinical and pathologic characteristics to predict the probability of postprostatectomy PSA failure are available. 4 According to the postoperative Baylor nomogram, 5 this patient has a 63% probability of PSA recurrence at 7 y (as compared with a 22% probability at 5 y based on pretreatment stage, PSA, and biopsy Gleason score). The PSA level of 0.07 ng/ml at 3 months postprostatectomy is encouraging, but the patient is aware that a PSA rise is likely to occur with time.
Adjuvant therapy in patients with lymph node metastases
Patients with lymph node metastases face an increased risk of disease progression and cancer-related death. 6, 7 Given the increased risk of disease progression associated with pN þ disease, adjuvant therapy and the options available should be discussed with pN þ patients.
A retrospective analysis suggests that postoperative radiotherapy improves cause-specific survival after radical prostatectomy and pelvic lymphadenectomy in men with adverse prognostic findings, including lymph node metastases. In this latter group (n ¼ 154), the 8-y risk of death from prostate cancer was 12% with adjuvant radiotherapy vs 32% with no adjuvant therapy (P ¼ 0.04). 8 While promising, these results need confirmation in a randomized setting. Further, many men with positive lymph nodes have occult distant micrometastases, which would not be eradicated by local radiotherapy. As a systemic therapy, there has been interest in adjuvant chemotherapy in high-risk postprostatectomy patients, such as those with lymph node metastases.
9 Good-quality data to support this approach are, however, lacking and given its inherent toxicity, chemotherapy is generally reserved until patients have become truly hormone refractory.
For men with locally advanced disease selecting hormonal therapy, there are two options: castrationbased therapy or antiandrogens. The use of immediate castration (goserelin ('Zoladex') or orchiectomy) in patients such as described in this case is supported by data from an Eastern Cooperative Oncology Group trial (ECOG 7887). 10 In this trial, adjuvant castration significantly improved 10-y overall survival (51 vs 28%; P ¼ 0.025). 7, 10 Other luteinizing hormone-releasing hormone agonists have not been evaluated in this setting. For the individual patient, decisions on adjuvant hormonal therapy may be driven by quality of life as well as efficacy considerations. Indeed, this patient was concerned about the side effects of castration, which was the primary reason for him choosing second-line nonsteroidal antiandrogen therapy (bicalutamide). Data at 5.4-y median follow-up from patients with locally advanced disease (including pN þ disease) who underwent radical prostatectomy (n ¼ 1719) in the ongoing Early Prostate Cancer program demonstrate that initiating bicalutamide 150 mg after radical prostatectomy significantly reduces the risk of disease progression by 29% (P ¼ 0.0034). 11 This benefit is achieved without many of the side effects of castration, such as impotence and loss of libido. 11 To date, in the adjuvant setting, a statistically significant improvement in overall survival has not been shown. 11 Of the other nonsteroidal antiandrogens, only flutamide has been studied as adjuvant to radical prostatectomy, but not in nodepositive patients.
12 Figure 1 Histopathology from the patient in question revealing metastatic adenocarcinoma of the prostate in one of the nine lymph nodes removed from the obturator fossa.
Management of lymph node-positive disease R Kirby
Despite the evidence of improved outcomes with adjuvant hormonal therapy, the patient elected to postpone such therapy until his PSA level begins to rise and, following his research on the Internet, is taking vitamin B17 in the form of apricot kernels, even though there is no scientific evidence to support their use. The patient is, however, convinced of their effectiveness: to disabuse him of this belief would risk damaging the doctor-patient relationship.
Conclusions
The clinical characteristics of this patient are typical of patients now being diagnosed with prostate cancer in the UK and increasingly these patients are undergoing radical prostatectomy. The patient underwent nervesparing radical prostatectomy, which was successful in preserving his sexual function. However, he had a positive posterolateral surgical margin and, although his predicted risk of lymph node metastases was very low, the prostatectomy pathology revealed metastatic disease. Patients with positive lymph nodes are at an increased risk of disease progression and cancer-related death; thus, adjuvant hormonal therapy should be considered taking into account efficacy alongside tolerability and quality-of-life considerations, and the patient's individual needs and concerns.
